Shilo Ben Zeev's Founder Playbook for Fundraising & Exits

Your Biggest Weakness Is Your Unfair Advantage

Many founders are told to project invincibility. Shilo Ben Zeev’s story offers a different playbook: turn your deepest challenges into your most defensible asset. Growing up, Shilo describes his childhood as “non-epic,” leaving home at 12 and not finishing high school. At age 8, he was diagnosed with type 1 diabetes.

Instead of hiding this, he made it his life’s work. The daily, painful, and conspicuous reality of managing diabetes gave him an insight that no market research report ever could. This personal pain became the engine for his first major company, Dario.

The Non-Obvious Insight: The most powerful founder-market fit comes from lived experience. Investors can buy market research; they can’t buy your unique, earned perspective. Your struggle is your moat.

How to Find Your “Dario” Idea

Don’t look for ideas. Look for problems—in your own life. What do you spend too much money on? What process feels broken? What tool do you wish existed every single day?

Map your daily frustrations. Make a literal list. · Ask: Is this a “me” problem or a “we” problem? Talk to 10 other people who share your demographic or condition. · Could technology solve this in a way that wasn’t possible 5 years ago? For Shilo, it was the rise of the smartphone.

Lesson 1: Pitching a Future Investors Can't See

Shilo’s idea for Dario was simple and revolutionary: connect a blood glucose meter to a smartphone. Today, that sounds obvious. In the early 2010s, it was heresy. The medical device world was dominated by large companies focused on drug and insulin sales, not user experience.

Investors were skeptical. “Why change what works?” they asked. They saw a market comfortable with clunky, separate devices. Shilo saw a younger generation that lived on their phones and refused the stigma of testing in public. He wasn’t just selling a device; he was selling a behavioral shift.

The Playbook for Category Creation

When you’re creating a new category, your pitch deck needs to do more than show a TAM slide. You’re fighting inertia and disbelief.

Common Mistake: Relying on top-down market sizing for a market that doesn’t exist. A slide saying “The Diabetes Market is $XB” was useless for Dario because it didn’t capture the new behavior he was enabling.

Build a “Deck of the Future”: Show, don’t just tell. Mock up the user experience with obsessive detail. Shilo’s vision was a device so seamless it felt like part of your phone. · Focus on the “Why Now”: What technological or cultural shift makes your idea possible for the first time? For Dario, it was smartphone ubiquity. · De-risk the User, Not the Market: Instead of fighting over TAM, prove a small group of users are obsessed with your solution. Your first $6M in funding comes from belief, backed by early user love.

Lesson 2: Navigating Regulatory Moats Like the FDA

Dario faced a massive hurdle: the Food and Drug Administration (FDA). The agency had never considered a smartphone a medical device. It took nearly a year of persistent, educational effort to get them on board.

Shilo recalls early, almost comical, questions from the FDA, like asking about the device’s battery. His response was simple: “You’re going to charge it.” This highlights a critical lesson for founders in regulated spaces.

The Counter-Intuitive Truth: Regulators aren't just gatekeepers; they are your most risk-averse design partners. Your job is to educate them and build their confidence in a future that doesn't look like the past.

Your FDA Pre-Submission Checklist

Before you even think about a 510(k) submission, you need to have answers for the narrative questions:

Human Factors: How does your design prevent user error? (e.g., Dario’s direct plug-in simplified the process). · Cybersecurity: How do you protect patient data on a connected device? · Equivalency vs. Novelty: Are you arguing your device is like something that exists, or are you preparing to prove the safety and efficacy of a brand-new approach? · The “Charging Problem”: Have you addressed every seemingly “dumb” question an outsider might ask? Often, the most basic questions hide the biggest assumptions.

Dario’s success didn’t just create a company; it forced a paradigm shift. Major medical device companies, who initially dismissed the idea, were forced to start focusing on user experience.

Lesson 3: The Second-Time Founder’s Paradox

After Dario went public and hit a peak valuation between $300M and $400M, you’d assume Shilo’s path would be easy. His next ventures prove that success doesn't grant immunity from startup physics.

Emendo Biotherapeutics: A gene-editing company. This was a massive success, sold to a Japanese pharmaceutical giant for $350M. · mybiotics Pharma: A microbiome engineering venture. · Smartzyme: A project to dramatically improve the accuracy of continuous glucose monitors (CGMs).

The story of Smartzyme is the most critical for founders. The team successfully developed the technology. They hit their milestones. But the venture was abruptly halted by its investors. Why? A competing product emerged, and the investors lost their nerve.

The Hard Truth About Investor Alignment

This is a non-obvious founder nightmare. You can do everything right—build the product, prove the science—and still have the rug pulled out from under you. Shilo’s experience is a powerful warning about the difference between capital and partnership.

Common Mistake: Assuming all money is equal. You don’t just want an investor; you want an investor with the right risk profile and time horizon for your specific journey, especially in deep tech or hardware.

Red Flags in Investor Relationships

Dismissiveness of your sector: Shilo notes the bias against consumer and medical device entrepreneurs. If a VC’s portfolio is 99% SaaS, they may not have the stomach for your hardware development cycle. · Lack of respect: He recounts dismissive attitudes and age bias. If an investor treats you like a subordinate during the pitch, imagine how they’ll act when you miss a quarter. · Misaligned incentives: Was your investor looking for a quick flip while you were building a decade-defining company? Smartzyme’s fate suggests a misalignment in vision and grit.

“Tell me about a time one of your portfolio companies faced a major, unexpected competitor. What was the board discussion like? What was your advice and contribution?”

“What is your typical involvement when a company is navigating a complex, multi-year regulatory process like the FDA?”

“Describe a situation where you continued to back a founder even after they missed initial product timelines. What gave you the conviction to do so?”

The Next Chapter: Emulait

Shilo’s journey—from personal health challenges to a massive exit, from public company success to a venture killed by investors—led him to his current company, Emulait. The venture aims to give babies the best feeding experience, reflecting his lifelong commitment to tackling deeply personal, impactful challenges.

Each lesson—the power of lived experience, the grit to pioneer a new category, the wisdom to navigate regulators, and the scars from misaligned investors—informs this new chapter. He isn't just building another company; he's deploying a hard-won playbook.

How to Apply This Playbook This Week

Audit Your Pains: List three personal or professional frustrations you have. For each one, write a single sentence on what a tech-enabled solution would look like. This is your raw material. · Re-frame a “No”: Take your last investor rejection. Write down what kind of risk they were unwilling to take (e.g., market risk, tech risk, team risk). Was it a bad fit, or do you need a better proof point? · Diligence a Potential Investor: Find one VC you admire. Don’t just look at their wins. Find a company in their portfolio that failed or struggled. Research what happened. This tells you more about them than any success story. · Draft Your “Regulator Pitch”: Even if you’re not in a regulated industry, pretend you are. Write one paragraph explaining your product to a skeptical, safety-obsessed outsider. This forces you to clarify your value proposition beyond the buzzwords.